ACS Chemical Biology

Cancer’s SOS

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.

COX-2 ‘conjugate’ may slow growth of some tumors: study

More than a decade after the anti-inflammatory drugs Vioxx and Bextra were pulled from the market because of a heightened risk of heart attack and stroke in some patients, COX-2 inhibitors may be on the verge of a comeback, this time as anti-cancer agents.

Schizophrenia ‘switches’ discovered

Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.